pmjТихоокеанский медицинский журналPacific Medical Journal1609-1175TGMU10.34215/1609-1175-2024-3-79-84pmj-2782Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHESЭффективность и безопасность фавипиравира и ремдесивира у больных СOVID-19: данные реальной клинической практикиEfficacy and safety of favipiravir and remdesivir in COVID-19 patients: Clinical dataПетровВ. И.PetrovV. I.

Волгоград

Volgograd

https://orcid.org/0000-0002-4778-5015РязановаА. Ю.RyazanovaA. Yu.

Рязанова Анастасия Юрьевна – доцент кафедры клинической фармакологии и интенсивной терапии

400066, г. Волгоград, площадь Павших Борцов, 1

тел. +7 (8442) 38-50-05

Anastasia Yu. Ryazanova, Associate Professor of the Department of Clinical Pharmacology and Intensive Care

1, Pavshikh Bortsov Sq., Volgograd, 400131, Russia

phone: +7 (8442) 38-50-05 

nastasyakus@mail.ruТокареваН. С.TokarevaN. S.

Волгоград

Volgograd

Волгоградский государственный медицинский университетРоссияVolgograd State Medical UniversityRussian Federation202404112024037984Copyright © Петров В.И., Рязанова А.Ю., Токарева Н.С., 20242024Петров В.И., Рязанова А.Ю., Токарева Н.С.Petrov V.I., Ryazanova A.Y., Tokareva N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tmj-vgmu.ru/jour/article/view/2782

Цель: оценить эффективность и безопасность применения фавипиравира и ремдесивира в инфекционном стационаре Волгоградской области в 2022 г. Материалы и методы. Проанализировано 559 медицинских карт пациентов, которым назначались фавипиравир или ремдесивир в 2022 г. Отдаленные результаты применения препаратов и исходов заболевания после выписки или перевода в другое лечебное учреждение оценивались с помощью федерального регистра лиц, больных СOVID-19. Результаты. Фавипиравир чаще назначался при легком течении заболевания. После исключения из анализа пациентов без признаков поражения легких достоверных различий между пациентами, получающими фавипиравир и ремдесевир, по показателям летальности и улучшения выявлено не было. У пациентов, получающих фавипиравир, шансы повышения активности аланинаминотрансферазы выше 5 верхних границ нормы и развития лекарственного поражения печени с возможной связью по шкале RUCAM были ниже по сравнению с пациентами, получающими ремдесивир (ОШ = 0,40, 95ДИ 0,20–0,80 и ОШ = 0,30, 95 ДИ 0,08–1,08). Заключение. Ограниченный опыт применения фавипиравира при СOVID-19 диктует необходимость дальнейшего изучения его эффективности и безопасности, особенно при одновременном приеме варфарина и высоких доз антикоагулянтов прямого действия.

Aim. To evaluate the efficacy and safety of favipiravir and remdesivir in the infectious disease hospital of the Volgograd region in 2022. Materials and methods. In total, 559 medical records of patients prescribed favipiravir or remdesivir in 2022 were studied. Long-term results of the drug use and disease outcomes after discharge or transfer to another medical institution were assessed using the Federal registry of people with COVID-19. Results. Favipiravir was more frequently prescribed in mild cases of the disease. After excluding patients without signs of lung injury from the analysis, there were no significant differences in mortality and improvement. Patients receiving favipiravir had lower odds of ALT elevations above 5 upper limits of normal and developing drug-induced liver injury with a possible RUCAM score compared with patients receiving remdesivir (OR = 0.40, 95CI 0.20–0.80 and OR = 0.30, 95 CI 0.08–1.08). Conclusion. The limited experience of the use of favipiravir for COVID-19 necessitates further research into its efficacy and safety, particularly when prescribing warfarin and high doses of direct anticoagulants simultaneously.

COVID-19реальная клиническая практикафавипиравирремдесивирлетальностьлекарственные поражения печениCOVID-19real-world datafavipiravirremdesivirmortalitydrug-induced liver injuryReferencesLiu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 2020;43(4):328–33. doi: 10.1016/j.bj.2020.04.007Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 2020;43(4):328–33. doi: 10.1016/j.bj.2020.04.007Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, Wang D, Liu C, Meng Y, Cui L, Yu J, Cao H, Li L. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J. Intern. Med. 2020;288(1):128–38. doi: 10.1111/joim.13063Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, Wang D, Liu C, Meng Y, Cui L, Yu J, Cao H, Li L. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J. Intern. Med. 2020;288(1):128–38. doi: 10.1111/joim.13063Sulaiman I, Chung M, Angel L, Tsay JJ, Wu BG, Yeung ST, Krolikowski K, Li Y, Duerr R, Schluger R, Thannickal SA, Koide A, Rafeq S, Barnett C, Postelnicu R, Wang C, Banakis S, Pérez-Pérez L, Shen G, Jour G, Meyn P, Carpenito J, Liu X, Ji K, Collazo D, Labarbiera A, Amoroso N, Brosnahan S, Mukherjee V, Kaufman D, Bakker J, Lubinsky A, Pradhan D, Sterman DH, Weiden M, Heguy A, Evans L, Uyeki TM, Clemente JC, de Wit E, Schmidt AM, Shopsin B, Desvignes L, Wang C, Li H, Zhang B, Forst CV, Koide S, Stapleford KA, Khanna KM, Ghedin E, Segal LN. Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome. Nat. Microbiol. 2021;6(10):1245–58. doi: 10.1038/s41564-021-00961-5Sulaiman I, Chung M, Angel L, Tsay JJ, Wu BG, Yeung ST, Krolikowski K, Li Y, Duerr R, Schluger R, Thannickal SA, Koide A, Rafeq S, Barnett C, Postelnicu R, Wang C, Banakis S, Pérez-Pérez L, Shen G, Jour G, Meyn P, Carpenito J, Liu X, Ji K, Collazo D, Labarbiera A, Amoroso N, Brosnahan S, Mukherjee V, Kaufman D, Bakker J, Lubinsky A, Pradhan D, Sterman DH, Weiden M, Heguy A, Evans L, Uyeki TM, Clemente JC, de Wit E, Schmidt AM, Shopsin B, Desvignes L, Wang C, Li H, Zhang B, Forst CV, Koide S, Stapleford KA, Khanna KM, Ghedin E, Segal LN. Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome. Nat. Microbiol. 2021;6(10):1245–58. doi: 10.1038/s41564-021-00961-5Lee TC, Murthy S, Del Corpo O, Senécal J, Butler-Laporte G, Sohani ZN, Brophy JM, McDonald EG. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(9):1203–10. doi: 10.1016/j.cmi.2022.04.018Lee TC, Murthy S, Del Corpo O, Senécal J, Butler-Laporte G, Sohani ZN, Brophy JM, McDonald EG. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(9):1203–10. doi: 10.1016/j.cmi.2022.04.018Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial. Lancet. 2020;395(10236):1569–78. doi: 10.1016/S0140-6736(20)31022-9Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial. Lancet. 2020;395(10236):1569–78. doi: 10.1016/S0140-6736(20)31022-9Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Gottlieb RL, Kuritzkes DR, Sax PE, Wohl DA, Casciano R, Hodgkins P, Haubrich R. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis. 2022;75(1):e450–e458. doi: 10.1093/cid/ciab875Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Gottlieb RL, Kuritzkes DR, Sax PE, Wohl DA, Casciano R, Hodgkins P, Haubrich R. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis. 2022;75(1):e450–e458. doi: 10.1093/cid/ciab875Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C, Israelsen SB, Jensen J, Jensen TØ, Johansen IS, Johnsen S, Lindegaard B, Lundgren J, Meyer CN, Mohey R, Pedersen LM, Nielsen H, Nielsen SL, Obel N, Omland LH, Podlekareva D, Poulsen BK, Ravn P, Sandholdt H, Starling J, Storgaard M, Søborg C, Søgaard OS, Tranborg T, Wiese L, Christensen HR. Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. Clin Infect Dis. 2021;73(11):2031–6. doi: 10.1093/cid/ciab536Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C, Israelsen SB, Jensen J, Jensen TØ, Johansen IS, Johnsen S, Lindegaard B, Lundgren J, Meyer CN, Mohey R, Pedersen LM, Nielsen H, Nielsen SL, Obel N, Omland LH, Podlekareva D, Poulsen BK, Ravn P, Sandholdt H, Starling J, Storgaard M, Søborg C, Søgaard OS, Tranborg T, Wiese L, Christensen HR. Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. Clin Infect Dis. 2021;73(11):2031–6. doi: 10.1093/cid/ciab536Государственный реестр лекарственных средств. URL: https://grls.rosminzdrav.ru (Accessed April 26, 2024).State Register of Medicines (In Russ.) URL: https://grls.rosminzdrav.ru (Accessed April 26, 2024).Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020;17(1):141. doi: 10.1186/s12985-020-01412-zShrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020;17(1):141. doi: 10.1186/s12985-020-01412-zManabe T, Kambayashi D, Akatsu H, Kudo К. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 2021;21(1):489. doi: 10.1186/s12879-021-06164-xManabe T, Kambayashi D, Akatsu H, Kudo К. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 2021;21(1):489. doi: 10.1186/s12879-021-06164-xTeschke R, Danan G. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM). Diagnostics (Basel). 2021;11(3):458. doi: 10.3390/diagnostics11030458Teschke R, Danan G. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM). Diagnostics (Basel). 2021;11(3):458. doi: 10.3390/diagnostics11030458Журавлева М.В., Кузнецова Е.В., Каменева Т.Р., Куликов А.Н., Ларюшкина Е.Д., Ивжиц М.А., Ромашов О.М., Родионов Б.А., Митрохин С.Д. Регистровое наблюдательное исследование по оценке эффективности и безопасности лекарственного препарата «Фавипиравир» у пациентов с COVID-19 в медицинских организациях государственной системы здравоохранения города москвы. Известия ГГТУ. Медицина, фармация. 2021;2:67–73.Zhuravleva MV, Kuznetsova EV, Kameneva TR, Kulikov AN, Laryushkina ED, Ivzhicz MA, Romashov OM, Rodionov BA, Galitskiy AA, Mitroxin SD, Mironov AYu. Register-based observational study of the efficacy and safety of favipiravir in patients with COVID-19 in medical organizations of the Moscow state healthcare system. Izvestiya GGTU. Medicina, Farmaciya. 2021;2:67–73 (In Russ.).Киселев Ю.Ю., Матвеев А.В., Мирзаев К.Б., Сычев Д.А. Мониторинг безопасности применения фавипиравира: управление рисками развития нежелательных лекарственных реакций в клинической практике. Качественная клиническая практика. 2020;S4:115–9. doi: 10.37489/2588-0519-2020-S4-115-119Kiselev YuYu, Matveev AV, Mirzaev KB, Sychev DA. Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;S4:115–9 (In Russ.) doi: 10.37489/2588-0519-2020-S4-115-119Руженцова Т.А., Чухляев П.В., Хавкина Д.А., Гарбузов А.А., Никольская М.В., Разживина В.А., Филон О.В. Необходимость и безопасность применения фавипиравира в лечении взрослых пациентов с нетяжелыми формами COVID-19. Эпидемиол. инфекц. болезни. Актуал. Вопр. 2021;10(4):38–44 doi:10.18565/epidem.2021.10.4.38–44Ruzhentsova TA, Chuchliaev PV, Khavkina DA, Garbuzov AA, Nikolskaya MV, Razzhivina VA, Filon OV. The necessity and safety of using favipiravir in the treatment of adult patients with mild COVID-19. Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy 2020;10(4):38–44. (In Russ.) doi: 10.18565/epidem.2021.10.4.38–44Петров В.И., Рязанова А.Ю., Привальцева Н.С., Некрасов Д.А. Опыт применения ремдесивира для лечения новой коронавирусной инфекции. Безопасность и риск фармакотерапии. 2022;10(4):365–80. doi:10.30895/2312-7821-2022-10-4-365-380Petrov VI, Ryazanova AYu, Privaltseva NS, Nekrasov DA. Experience of using remdesivir in patients with novel coronavirus infection. Safety and Risk of Pharmacotherapy. 2022;10(4):365–80 (In Russ.) doi: 10.30895/2312-7821-2022-10-4-365-380

The authors declare that there are no conflicts of interest present.